Review



specic primary antibodies against timp3  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology specic primary antibodies against timp3
    Fig. 3 <t>TIMP3</t> was a direct target of miR-132 in HaCaT cells. (A) The miR-132 binding sites predicted in the 30-UTR of TIMP3 mRNA and the mutant in seed sites. (B) The relative luciferase activity was detected in HaCaT cells cotransfected with TIMP3-WT or TIMP3-MUT constructs and miR-NC mimics or miR-132 mimics. (C) HaCaT cells were transfected with miR-NC mimics or miR-132 mimics, and the enrichment of TIMP3 mRNA was measured with anti-Ago2 or anti-IgG by qRT-PCR assay. (D) HaCaT cells were transfected with miR-NC mimics, miR-132 mimics, anti-miR-NC or anti-miR-132, followed by the detection of TIMP3 level by Western blot. **P < 0.01 or ***P < 0.001 vs. respective control.
    Specic Primary Antibodies Against Timp3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 124 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/specic+primary+antibodies+against+timp3/pm35521312-57-19-25?v=Santa+Cruz+Biotechnology
    Average 94 stars, based on 124 article reviews
    specic primary antibodies against timp3 - by Bioz Stars, 2026-08
    94/100 stars

    Images

    1) Product Images from "Retracted Article: MiR-132 enhances proliferation and migration of HaCaT cells by targeting TIMP3."

    Article Title: Retracted Article: MiR-132 enhances proliferation and migration of HaCaT cells by targeting TIMP3.

    Journal: RSC advances

    doi: 10.1039/c8ra10552a

    Fig. 3 TIMP3 was a direct target of miR-132 in HaCaT cells. (A) The miR-132 binding sites predicted in the 30-UTR of TIMP3 mRNA and the mutant in seed sites. (B) The relative luciferase activity was detected in HaCaT cells cotransfected with TIMP3-WT or TIMP3-MUT constructs and miR-NC mimics or miR-132 mimics. (C) HaCaT cells were transfected with miR-NC mimics or miR-132 mimics, and the enrichment of TIMP3 mRNA was measured with anti-Ago2 or anti-IgG by qRT-PCR assay. (D) HaCaT cells were transfected with miR-NC mimics, miR-132 mimics, anti-miR-NC or anti-miR-132, followed by the detection of TIMP3 level by Western blot. **P < 0.01 or ***P < 0.001 vs. respective control.
    Figure Legend Snippet: Fig. 3 TIMP3 was a direct target of miR-132 in HaCaT cells. (A) The miR-132 binding sites predicted in the 30-UTR of TIMP3 mRNA and the mutant in seed sites. (B) The relative luciferase activity was detected in HaCaT cells cotransfected with TIMP3-WT or TIMP3-MUT constructs and miR-NC mimics or miR-132 mimics. (C) HaCaT cells were transfected with miR-NC mimics or miR-132 mimics, and the enrichment of TIMP3 mRNA was measured with anti-Ago2 or anti-IgG by qRT-PCR assay. (D) HaCaT cells were transfected with miR-NC mimics, miR-132 mimics, anti-miR-NC or anti-miR-132, followed by the detection of TIMP3 level by Western blot. **P < 0.01 or ***P < 0.001 vs. respective control.

    Techniques Used: Binding Assay, Mutagenesis, Luciferase, Activity Assay, Construct, Transfection, Quantitative RT-PCR, Western Blot, Control

    Fig. 4 TGF-b1 repressed the expression of TIMP3. HaCaT (A) and NHEK (B) cells were treated with different concentration (0, 2, 5 and 10 ng ml1) of TGF- b1 for 24 h, and then TIMP3 expression was detected by Western blot. HaCaT (C) and NHEK (D) cells were treated with 5 ng ml1 of TGF-b1 at different time period (0, 6, 12 and 24 h), followed by the measurement of TIMP3 expression by Western blot. *P < 0.05 or **P < 0.01 or ***P < 0.001 vs. control.
    Figure Legend Snippet: Fig. 4 TGF-b1 repressed the expression of TIMP3. HaCaT (A) and NHEK (B) cells were treated with different concentration (0, 2, 5 and 10 ng ml1) of TGF- b1 for 24 h, and then TIMP3 expression was detected by Western blot. HaCaT (C) and NHEK (D) cells were treated with 5 ng ml1 of TGF-b1 at different time period (0, 6, 12 and 24 h), followed by the measurement of TIMP3 expression by Western blot. *P < 0.05 or **P < 0.01 or ***P < 0.001 vs. control.

    Techniques Used: Expressing, Concentration Assay, Western Blot, Control

    Fig. 5 TIMP3 inhibited the proliferation and migration of HaCaT cells under TGF-b1 treatment. HaCaT cells were treated with TGF-b1 (5 ng ml1) or transfected with pcDNA or pcDNA-TIMP3 prior to TGF-b1 treatment. (A) and (B) qRT-PCR for miR-132 expression in treated cells. (C) and (D) MTT assay for the proliferation ability in treated cells. (E) and (F) Transwell assay for the migration capacity in treated cells. *P < 0.05 or **P < 0.01 vs. control or TGF-b1 + pcDNA.
    Figure Legend Snippet: Fig. 5 TIMP3 inhibited the proliferation and migration of HaCaT cells under TGF-b1 treatment. HaCaT cells were treated with TGF-b1 (5 ng ml1) or transfected with pcDNA or pcDNA-TIMP3 prior to TGF-b1 treatment. (A) and (B) qRT-PCR for miR-132 expression in treated cells. (C) and (D) MTT assay for the proliferation ability in treated cells. (E) and (F) Transwell assay for the migration capacity in treated cells. *P < 0.05 or **P < 0.01 vs. control or TGF-b1 + pcDNA.

    Techniques Used: Migration, Transfection, Quantitative RT-PCR, Expressing, MTT Assay, Transwell Assay, Control

    Fig. 6 MiR-132-mediated pro-proliferation and pro-migration effects were antagonized by TIMP3 in TGF-b1-treated HaCaT cells. HaCaT cells were transfected with miR-132 mimics + pcDNA, miR-132 mimics + pcDNA-TIMP3, anti-miR-132 + si-NC or anti-miR-132 + si-TIMP3 prior to TGF-b1 (5 ng ml1) treatment, followed by the detection of cell proliferation ability by MTT assay (A) and (B), cell migration capacity by transwell assay (C) and (D). *P < 0.05 or **P < 0.01 vs. control or TGF-b1 + miR-NC or TGF-b1 + miR-132 + pcDNA.
    Figure Legend Snippet: Fig. 6 MiR-132-mediated pro-proliferation and pro-migration effects were antagonized by TIMP3 in TGF-b1-treated HaCaT cells. HaCaT cells were transfected with miR-132 mimics + pcDNA, miR-132 mimics + pcDNA-TIMP3, anti-miR-132 + si-NC or anti-miR-132 + si-TIMP3 prior to TGF-b1 (5 ng ml1) treatment, followed by the detection of cell proliferation ability by MTT assay (A) and (B), cell migration capacity by transwell assay (C) and (D). *P < 0.05 or **P < 0.01 vs. control or TGF-b1 + miR-NC or TGF-b1 + miR-132 + pcDNA.

    Techniques Used: Migration, Transfection, MTT Assay, Transwell Assay, Control



    Similar Products

    specic primary antibodies against timp3  (Santa Cruz Biotechnology)
    94
    Santa Cruz Biotechnology specic primary antibodies against timp3
    Fig. 3 <t>TIMP3</t> was a direct target of miR-132 in HaCaT cells. (A) The miR-132 binding sites predicted in the 30-UTR of TIMP3 mRNA and the mutant in seed sites. (B) The relative luciferase activity was detected in HaCaT cells cotransfected with TIMP3-WT or TIMP3-MUT constructs and miR-NC mimics or miR-132 mimics. (C) HaCaT cells were transfected with miR-NC mimics or miR-132 mimics, and the enrichment of TIMP3 mRNA was measured with anti-Ago2 or anti-IgG by qRT-PCR assay. (D) HaCaT cells were transfected with miR-NC mimics, miR-132 mimics, anti-miR-NC or anti-miR-132, followed by the detection of TIMP3 level by Western blot. **P < 0.01 or ***P < 0.001 vs. respective control.
    Specic Primary Antibodies Against Timp3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/specic+primary+antibodies+against+timp3/pm35521312-57-19-25?v=Santa+Cruz+Biotechnology
    Average 94 stars, based on 1 article reviews
    specic primary antibodies against timp3 - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 3 TIMP3 was a direct target of miR-132 in HaCaT cells. (A) The miR-132 binding sites predicted in the 30-UTR of TIMP3 mRNA and the mutant in seed sites. (B) The relative luciferase activity was detected in HaCaT cells cotransfected with TIMP3-WT or TIMP3-MUT constructs and miR-NC mimics or miR-132 mimics. (C) HaCaT cells were transfected with miR-NC mimics or miR-132 mimics, and the enrichment of TIMP3 mRNA was measured with anti-Ago2 or anti-IgG by qRT-PCR assay. (D) HaCaT cells were transfected with miR-NC mimics, miR-132 mimics, anti-miR-NC or anti-miR-132, followed by the detection of TIMP3 level by Western blot. **P < 0.01 or ***P < 0.001 vs. respective control.

    Journal: RSC advances

    Article Title: Retracted Article: MiR-132 enhances proliferation and migration of HaCaT cells by targeting TIMP3.

    doi: 10.1039/c8ra10552a

    Figure Lengend Snippet: Fig. 3 TIMP3 was a direct target of miR-132 in HaCaT cells. (A) The miR-132 binding sites predicted in the 30-UTR of TIMP3 mRNA and the mutant in seed sites. (B) The relative luciferase activity was detected in HaCaT cells cotransfected with TIMP3-WT or TIMP3-MUT constructs and miR-NC mimics or miR-132 mimics. (C) HaCaT cells were transfected with miR-NC mimics or miR-132 mimics, and the enrichment of TIMP3 mRNA was measured with anti-Ago2 or anti-IgG by qRT-PCR assay. (D) HaCaT cells were transfected with miR-NC mimics, miR-132 mimics, anti-miR-NC or anti-miR-132, followed by the detection of TIMP3 level by Western blot. **P < 0.01 or ***P < 0.001 vs. respective control.

    Article Snippet: Blocked by a buffer containing 5% non-fat milk in TBS with 0.1% Tween-20, the membrances were probed overnight with specic primary antibodies against TIMP3 (sc-373839, Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution 1 : 500) or b-actin (sc517582, Santa Cruz Biotechnology; dilution 1 : 1000) at 4 C, followed by the incubation with HRP-conjugated secondary antibodies (sc-516102, Santa Cruz Biotechnology; dilution 1 : 5000).

    Techniques: Binding Assay, Mutagenesis, Luciferase, Activity Assay, Construct, Transfection, Quantitative RT-PCR, Western Blot, Control

    Fig. 4 TGF-b1 repressed the expression of TIMP3. HaCaT (A) and NHEK (B) cells were treated with different concentration (0, 2, 5 and 10 ng ml1) of TGF- b1 for 24 h, and then TIMP3 expression was detected by Western blot. HaCaT (C) and NHEK (D) cells were treated with 5 ng ml1 of TGF-b1 at different time period (0, 6, 12 and 24 h), followed by the measurement of TIMP3 expression by Western blot. *P < 0.05 or **P < 0.01 or ***P < 0.001 vs. control.

    Journal: RSC advances

    Article Title: Retracted Article: MiR-132 enhances proliferation and migration of HaCaT cells by targeting TIMP3.

    doi: 10.1039/c8ra10552a

    Figure Lengend Snippet: Fig. 4 TGF-b1 repressed the expression of TIMP3. HaCaT (A) and NHEK (B) cells were treated with different concentration (0, 2, 5 and 10 ng ml1) of TGF- b1 for 24 h, and then TIMP3 expression was detected by Western blot. HaCaT (C) and NHEK (D) cells were treated with 5 ng ml1 of TGF-b1 at different time period (0, 6, 12 and 24 h), followed by the measurement of TIMP3 expression by Western blot. *P < 0.05 or **P < 0.01 or ***P < 0.001 vs. control.

    Article Snippet: Blocked by a buffer containing 5% non-fat milk in TBS with 0.1% Tween-20, the membrances were probed overnight with specic primary antibodies against TIMP3 (sc-373839, Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution 1 : 500) or b-actin (sc517582, Santa Cruz Biotechnology; dilution 1 : 1000) at 4 C, followed by the incubation with HRP-conjugated secondary antibodies (sc-516102, Santa Cruz Biotechnology; dilution 1 : 5000).

    Techniques: Expressing, Concentration Assay, Western Blot, Control

    Fig. 5 TIMP3 inhibited the proliferation and migration of HaCaT cells under TGF-b1 treatment. HaCaT cells were treated with TGF-b1 (5 ng ml1) or transfected with pcDNA or pcDNA-TIMP3 prior to TGF-b1 treatment. (A) and (B) qRT-PCR for miR-132 expression in treated cells. (C) and (D) MTT assay for the proliferation ability in treated cells. (E) and (F) Transwell assay for the migration capacity in treated cells. *P < 0.05 or **P < 0.01 vs. control or TGF-b1 + pcDNA.

    Journal: RSC advances

    Article Title: Retracted Article: MiR-132 enhances proliferation and migration of HaCaT cells by targeting TIMP3.

    doi: 10.1039/c8ra10552a

    Figure Lengend Snippet: Fig. 5 TIMP3 inhibited the proliferation and migration of HaCaT cells under TGF-b1 treatment. HaCaT cells were treated with TGF-b1 (5 ng ml1) or transfected with pcDNA or pcDNA-TIMP3 prior to TGF-b1 treatment. (A) and (B) qRT-PCR for miR-132 expression in treated cells. (C) and (D) MTT assay for the proliferation ability in treated cells. (E) and (F) Transwell assay for the migration capacity in treated cells. *P < 0.05 or **P < 0.01 vs. control or TGF-b1 + pcDNA.

    Article Snippet: Blocked by a buffer containing 5% non-fat milk in TBS with 0.1% Tween-20, the membrances were probed overnight with specic primary antibodies against TIMP3 (sc-373839, Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution 1 : 500) or b-actin (sc517582, Santa Cruz Biotechnology; dilution 1 : 1000) at 4 C, followed by the incubation with HRP-conjugated secondary antibodies (sc-516102, Santa Cruz Biotechnology; dilution 1 : 5000).

    Techniques: Migration, Transfection, Quantitative RT-PCR, Expressing, MTT Assay, Transwell Assay, Control

    Fig. 6 MiR-132-mediated pro-proliferation and pro-migration effects were antagonized by TIMP3 in TGF-b1-treated HaCaT cells. HaCaT cells were transfected with miR-132 mimics + pcDNA, miR-132 mimics + pcDNA-TIMP3, anti-miR-132 + si-NC or anti-miR-132 + si-TIMP3 prior to TGF-b1 (5 ng ml1) treatment, followed by the detection of cell proliferation ability by MTT assay (A) and (B), cell migration capacity by transwell assay (C) and (D). *P < 0.05 or **P < 0.01 vs. control or TGF-b1 + miR-NC or TGF-b1 + miR-132 + pcDNA.

    Journal: RSC advances

    Article Title: Retracted Article: MiR-132 enhances proliferation and migration of HaCaT cells by targeting TIMP3.

    doi: 10.1039/c8ra10552a

    Figure Lengend Snippet: Fig. 6 MiR-132-mediated pro-proliferation and pro-migration effects were antagonized by TIMP3 in TGF-b1-treated HaCaT cells. HaCaT cells were transfected with miR-132 mimics + pcDNA, miR-132 mimics + pcDNA-TIMP3, anti-miR-132 + si-NC or anti-miR-132 + si-TIMP3 prior to TGF-b1 (5 ng ml1) treatment, followed by the detection of cell proliferation ability by MTT assay (A) and (B), cell migration capacity by transwell assay (C) and (D). *P < 0.05 or **P < 0.01 vs. control or TGF-b1 + miR-NC or TGF-b1 + miR-132 + pcDNA.

    Article Snippet: Blocked by a buffer containing 5% non-fat milk in TBS with 0.1% Tween-20, the membrances were probed overnight with specic primary antibodies against TIMP3 (sc-373839, Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution 1 : 500) or b-actin (sc517582, Santa Cruz Biotechnology; dilution 1 : 1000) at 4 C, followed by the incubation with HRP-conjugated secondary antibodies (sc-516102, Santa Cruz Biotechnology; dilution 1 : 5000).

    Techniques: Migration, Transfection, MTT Assay, Transwell Assay, Control